| Value | ₹1.16 Cr |
|---|---|
| Execution period | 18 months |
BSE filing, NSE: STANDARD. Summary written from the filing by ALFA Finder's alert engine.
Standard Surfactants Ltd: key numbers
- Share price
- ₹126.70
- Market cap
- ₹104.7 Cr
- Revenue (annual)
- ₹244.2 Cr
- Net profit (annual)
- ₹3.33 Cr
- P/E (TTM)
- 11.4×Sector 34.1×
- Promoter holding
- 62.14%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Standard Surfactants Ltd
All →Standard Surfactants Other Announcement
The company submitted its quarterly shareholding pattern as per Regulation 31, detailing the distribution of shareholding among various categories of shareholders.
Standard Surfactants Annual General Meeting
Standard Surfactants Ltd held its 37th Annual General Meeting on 30th September 2026. The meeting covered adoption of financial statements and related party transaction approvals.
Standard Surfactants Annual General Meeting
Standard Surfactants Ltd has submitted its 37th Annual Report for FY 2025-26 and notice for the AGM scheduled on September 30, 2026.
Standard Surfactants Promoter Buying (Off-Market): ₹0.34 Cr
Promoter group members executed inter-se off-market transfers involving 58,000 shares totaling ₹0.34 Crore. The transactions reflect internal realignment within the Garg family.
- Value
- ₹0.34 Cr
Standard Surfactants Q1 FY27 Results: Net Profit ₹6.3 Cr, Up 1160.0% YoY
Standard Surfactants Ltd reported revenue from operations of ₹102.4 Cr (+93.2% YoY) and net profit of ₹6.3 Cr (+1160.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹6.3 Cr · +1160.0% YoY
Standard Surfactants Board Meeting Outcome
Standard Surfactants Ltd held a board meeting approving the Q1 FY 2026-27 unaudited financial results. The company also announced the upcoming 37th AGM date and auditor appointment.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr